Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors - Scorecard - MDSpire
Advertisement
Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors
Clinical Scorecard: Multicenter, open-label Phase I/II trial assessing the efficacy of durvalumab combined with tremelimumab in children with advanced solid tumors
At a Glance
Category
Detail
Condition
Relapsed/Refractory Solid Tumors in Pediatric Patients
Key Mechanisms
Durvalumab (anti-PD-L1) and Tremelimumab (anti-CTLA-4) enhance T cell activation and antitumor immunity.
Target Population
Pediatric patients with advanced solid tumors
Care Setting
Multicenter, open-label clinical trial
Key Highlights
Durvalumab (30 mg/kg) + Tremelimumab (1 mg/kg) was evaluated for safety and efficacy.
Limited antitumor activity observed; one patient with chordoma had a partial response.
76% of patients experienced treatment-related adverse events, with 19% as grade 3 or 4.
No treatment-related deaths reported.
Increased CD4+Ki67+ T cells noted post-treatment.
Guideline-Based Recommendations
Diagnosis
Assess relapsed/refractory solid tumors in pediatric patients.
Management
Consider durvalumab and tremelimumab combination therapy for eligible patients.
Monitoring & Follow-up
Monitor for treatment-related adverse events and immune cell activation.
Risks
Potential for significant adverse events, including grade 3 or 4 complications.
Patient & Prescribing Data
Children with relapsed/refractory solid tumors.
Combination therapy shows manageable safety profile but limited efficacy.
Clinical Best Practices
Utilize immune checkpoint inhibitors in pediatric oncology with caution.
Monitor immune response markers to assess treatment impact.
